Relative Bioavailability of Cenobamate Administered as a Crushed Tablet, Either Orally or via Nasogastric Tube, versus an Intact Whole Tablet

Abstract

AbstractCenobamate is approved for the treatment of focal seizures in adults and is currently available as an oral tablet. Alternative methods of drug administration are needed for patients who are unable to swallow whole intact tablets. This phase 1, open‐label, randomized, single‐dose, three‐way crossover (3‐period, 3‐treatment, 6‐sequence) study (NCT05572255), conducted in healthy volunteers, assessed the relative bioavailability of a crushed 200‐mg cenobamate tablet administered orally or via nasogastric (NG) tube compared with an intact 200‐mg tablet. Each treatment was separated by a 13‐day washout period. Plasma samples for cenobamate concentration analysis were collected pre‐dose and at multiple time points up to 264 h post‐dose. Standard bioequivalence study criteria were applied to the relative bioavailability assessments. All 90% confidence intervals of test‐to‐reference geometric mean ratios for cenobamate pharmacokinetic parameters (Cmax, AUClast, and AUCinf) were within 85‐110% (predefined limit, 80‐125%), suggesting no difference in cenobamate exposures following administration of an intact tablet orally or a crushed tablet orally or via NG tube. All treatment‐emergent adverse events (TEAEs) were classified as mild and resolved. There were no deaths or other serious AEs (SAEs), and no TEAEs led to discontinuation. Our results indicate that the administration of cenobamate as a crushed tablet taken orally or via an NG tube can provide additional flexibility when patients cannot swallow intact tablets. Based on the results of this study, cenobamate is now approved by FDA to be taken whole or the tablets can be crushed. The crushed tablet can be mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.